Presbyopia-Pipeline Review, H2 2016

Presbyopia-Pipeline Review, H2 2016

  • Products Id :- GMDHC8918IDB
  • |
  • Pages: 36
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Presbyopia-Pipeline Review, H2 2016


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia-Pipeline Review, H2 2016, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape.

Presbyopiais an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis and eye trauma.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Presbyopia-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Presbyopia (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Presbyopia (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Presbyopia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 5, 1 and 1 respectively.

Presbyopia (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


The pipeline guide provides a snapshot of the global therapeutic landscape of Presbyopia (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Presbyopia (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Presbyopia (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Presbyopia (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Presbyopia (Ophthalmology)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Presbyopia (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Presbyopia (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Presbyopia Overview 6

Therapeutics Development 7

Pipeline Products for Presbyopia-Overview 7

Presbyopia-Therapeutics under Development by Companies 8

Presbyopia-Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Presbyopia-Products under Development by Companies 11

Presbyopia-Companies Involved in Therapeutics Development 12

Allergan Plc 12

Encore Vision Inc 13

Orasis Pharmaceuticals Ltd 14

Presbyopia Therapies LLC 15

ViewPoint Therapeutics Inc 16

Presbyopia-Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Combination Products 18

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 26

(aceclidine + tropicamide)-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

(oxymetazoline hydrochloride + pilocarpine hydrochloride)-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

EV-06-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

lanosterol-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

oxymetazoline hydrochloride-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

PresbiDrops-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

VP-1001-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Appendix 35

Methodology 35

Coverage 35

Secondary Research 35

Primary Research 35

Expert Panel Validation 35

Contact Us 35

Disclaimer 36

List of Figures

Number of Products under Development for Presbyopia, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Targets, H2 2016 19

Number of Products by Stage and Targets, H2 2016 19

Number of Products by Mechanism of Actions, H2 2016 21

Number of Products by Stage and Mechanism of Actions, H2 2016 21

Number of Products by Routes of Administration, H2 2016 23

Number of Products by Stage and Routes of Administration, H2 2016 23

Number of Products by Stage and Molecule Types, H2 2016 25

List of Tables

Number of Products under Development for Presbyopia, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Presbyopia-Pipeline by Allergan Plc, H2 2016 12

Presbyopia-Pipeline by Encore Vision Inc, H2 2016 13

Presbyopia-Pipeline by Orasis Pharmaceuticals Ltd, H2 2016 14

Presbyopia-Pipeline by Presbyopia Therapies LLC, H2 2016 15

Presbyopia-Pipeline by ViewPoint Therapeutics Inc, H2 2016 16

Assessment by Monotherapy Products, H2 2016 17

Assessment by Combination Products, H2 2016 18

Number of Products by Stage and Target, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 22

Number of Products by Stage and Route of Administration, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Allergan Plc, Encore Vision Inc, Orasis Pharmaceuticals Ltd, Presbyopia Therapies LLC, ViewPoint Therapeutics Inc

Presbyopia Therapeutic Products under Development, Key Players in Presbyopia Therapeutics, Presbyopia Pipeline Overview, Presbyopia Pipeline, Presbyopia Pipeline Assessment

select a license
Single User License
USD 2000 INR 144740
Site License
USD 4000 INR 289480
Corporate User License
USD 6000 INR 434220



I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]